Central Nervous System Diseases  >>  verubecestat (MK-8931)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
verubecestat (MK-8931) / Merck (MSD)
APECS, NCT01953601 / 2012-005542-38: Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)

Hourglass Jan 2019 - Dec 2019 : Final results
Checkmark APECS trial in Alzheimer's disease
Feb 2019 - Feb 2019: APECS trial in Alzheimer's disease
Checkmark eDMC recommendation due to lack of positive benefit/risk
Feb 2018 - Feb 2018: eDMC recommendation due to lack of positive benefit/risk
More
Terminated
3
1454
NA
Verubecestat 12 mg (Parts 1 and 2), MK-8931, Verubecestat 40 mg (Parts 1 and 2), Placebo (Part 1)
Merck Sharp & Dohme LLC
Amnestic Mild Cognitive Impairment, Alzheimer's Disease, Prodromal Alzheimer's Disease
04/18
04/18
EPOCH, NCT01739348 / 2011-003151-20: An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738)

Checkmark eDMC recommended to stop due to lack of efficacy
Feb 2017 - Feb 2017: eDMC recommended to stop due to lack of efficacy
Checkmark CTAD 2016
Dec 2016 - Dec 2016: CTAD 2016
Checkmark Interim safety analysis recommendation (P2/3, N=1,960; EPOCH)
More
Terminated
2/3
2211
NA
Verubecestat (Part I and Part II), SCH 900931, Placebo (Part I), Verubecestat (Part II)
Merck Sharp & Dohme LLC
Alzheimer's Disease
04/17
04/17

Download Options